Morgan Stanley Goes Overweight on Endava

Morgan Stanley ($MS@US) has maintained its overweight rating for Endava stock as it raised its price target to $190. Analyst ratings are often the best information you can gather as you seek out the right stock to add to your portfolio. In reviewing information from Benzinga, it appears that Morgan Stanley has continued to increase its price target, which was once $140 in early January of this year. Moreover, that target range seems to be a consensus as Citigroup ($C@US) lowered its price target to that same level. Moreover, reviewing analyst ratings indicates that the target price has been rising for nearly 2 years. For Endava’s part, it’s released guidance indicating a max EPS of 59 cents. Return to Benzinga for more information that will help you make wise investment decisions.